Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ovarian cancer: drug combo targets relapsed patients

NCT ID NCT07370818

Disease control Sponsor: Onconic Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps keep the cancer from growing longer. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JPI-547 (a drug) combined with bevacizumab (another drug)
What this could lead to
If successful, this could offer a new maintenance treatment option for relapsed ovarian cancer patients who have already tried PARP inhibitors.
What could go wrong
This is an early Phase 2 trial with only 81 participants, so results may not apply to all patients. The drug may not improve survival or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 81 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer \[High-grade serous carcinoma (HGSC), Grade 2/3 endometrioid carcinoma\] * Patients whose BRCA 1/2 gene mutation status and/or Homologous Recombination Deficiency (HRD) status. * Patients who received platinum-based chemotherapy followed by PARP inhibitor maintenance therapy, * Patients who had received chemotherapy before participating in the clinical trial and responded to platinum-based chemotherapy. * Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Individuals with confirmed adequate hematological, renal, and hepatic function (laboratory tests may be repeated once during the screening period) Exclusion Criteria: * Patients with a history of severe drug hypersensitivity or hypersensitivity to the investigational drug, its components, or drugs within the same class. * Individuals with dysphagia * Patients with a confirmed specific medical history or a past surgical history. * Patients with specific comorbidities or medical abnormalities. * Pregnant women, lactating women, or women of childbearing potential who do not agree to use appropriate contraception during the clinical trial period and for 24 weeks after administration of the investigational medicinal product. * Those who have administered other investigational products or have received investigational medical device procedures within 4 weeks of the baseline * Other patients who are inappropriate or unable to participate in this clinical study at the discretion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.